Johannes M Ludwig1, Emily McIntosh Ambinder2, Anish Ghodadra3, Minzhi Xing1, Hasmukh J Prajapati4, Hyun S Kim5,6. 1. Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale University, 330 Cedar Street, TE 2-224, New Haven, CT, 06510, USA. 2. Department of Diagnostic Radiology, John Hopkins University School of Medicine, 601 N Caroline Street, Baltimore, MD, 21287, USA. 3. Interventional Radiology, Department of Radiology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. 4. Division of Interventional Radiology, Department of Radiology, The University of Tennessee Health Science Center, 865 Jefferson Ave, Memphis, TN, 38103, USA. 5. Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale University, 330 Cedar Street, TE 2-224, New Haven, CT, 06510, USA. kevin.kim@yale.edu. 6. Yale Cancer Center, 333 Cedar Street, New Haven, CT, 06510, USA. kevin.kim@yale.edu.
Abstract
OBJECTIVE: To investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate lung shunt fraction (LSF) as a predictor for survival. METHODS: A single-center, prospective study of 44 consecutive patients (median age: 58.5 years, 29.5 % male) diagnosed with pancreatic (52.3 %) or carcinoid (47.7 %) NETLMs from 2006 to 2012 who underwent Y90 radioembolization was performed. Patients' baseline characteristics, including LSF and median overall survival (OS) from first Y90 radioembolization, were recorded and compared between patients with high (≥10 %) and low (<10 %) LSF. Baseline comparisons were performed using Fisher's exact tests for categorical and Mann-Whitney U test for continuous variables. Survival was calculated using the Kaplan-Meier method. Univariate (Wilcoxon rank-sum test) and multivariate analyses (Cox Proportional Hazard Model) for risk factor analysis were performed. RESULTS: There was no statistically significant difference in age, gender, race, tumor properties, or previous treatments between patients with high (n = 15) and low (n = 29) LSF. The median OS was 27.4 months (95 %CI 12.73-55.23), with 4.77 months (95 %CI 2.87-26.73) for high and 42.77 months (95 %CI 18.47-59.73) for low LSF (p = 0.003). Multivariate analysis identified high LSF (p = 0.001), total serum bilirubin >1.2 mg (p = 0.016), and lack of pretreatment with octreotide (p = 0.01) as independent prognostic factors for poorer survival. Tumor type and total radiation dose did not predict survival. CONCLUSIONS: LSF ≥10 %, elevated bilirubin levels, and lack of pretreatment with octreotide were found to be independent prognostic factors for poorer survival in patients with NETLMs.
OBJECTIVE: To investigate survival outcomes following radioembolization with Yttrium-90 (Y90) for neuroendocrine tumor liver metastases (NETLMs). This study was designed to assess the efficacy of Y90 radioembolization and to evaluate lung shunt fraction (LSF) as a predictor for survival. METHODS: A single-center, prospective study of 44 consecutive patients (median age: 58.5 years, 29.5 % male) diagnosed with pancreatic (52.3 %) or carcinoid (47.7 %) NETLMs from 2006 to 2012 who underwent Y90 radioembolization was performed. Patients' baseline characteristics, including LSF and median overall survival (OS) from first Y90 radioembolization, were recorded and compared between patients with high (≥10 %) and low (<10 %) LSF. Baseline comparisons were performed using Fisher's exact tests for categorical and Mann-Whitney U test for continuous variables. Survival was calculated using the Kaplan-Meier method. Univariate (Wilcoxon rank-sum test) and multivariate analyses (Cox Proportional Hazard Model) for risk factor analysis were performed. RESULTS: There was no statistically significant difference in age, gender, race, tumor properties, or previous treatments between patients with high (n = 15) and low (n = 29) LSF. The median OS was 27.4 months (95 %CI 12.73-55.23), with 4.77 months (95 %CI 2.87-26.73) for high and 42.77 months (95 %CI 18.47-59.73) for low LSF (p = 0.003). Multivariate analysis identified high LSF (p = 0.001), total serum bilirubin >1.2 mg (p = 0.016), and lack of pretreatment with octreotide (p = 0.01) as independent prognostic factors for poorer survival. Tumor type and total radiation dose did not predict survival. CONCLUSIONS: LSF ≥10 %, elevated bilirubin levels, and lack of pretreatment with octreotide were found to be independent prognostic factors for poorer survival in patients with NETLMs.
Authors: Cassidy R Dodson; Colin Marshall; Jared C Durieux; Patrick F Wojtylak; Jon C Davidson; Raymond F Muzic; Arash Kardan Journal: Cardiovasc Intervent Radiol Date: 2022-08-04 Impact factor: 2.797
Authors: Mohammad Elsayed; Bernard Cheng; Minzhi Xing; Ila Sethi; David Brandon; David M Schuster; Zachary Bercu; James Galt; Bruce Barron; Nima Kokabi Journal: Cardiovasc Intervent Radiol Date: 2020-10-01 Impact factor: 2.740
Authors: Katsuyuki Taguchi; Thomas J Sauer; W Paul Segars; Eric C Frey; Jingyan Xu; Eleni Liapi; J Webster Stayman; Kelvin Hong; Ferdinand K Hui; Mathias Unberath; Yong Du Journal: Med Phys Date: 2020-10-22 Impact factor: 4.071
Authors: Arighno Das; Ahsun Riaz; Ahmed Gabr; Rehan Ali; Ronald Mora; Ali Al Asadi; Samdeep Mouli; Robert J Lewandowski; Riad Salem Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-10 Impact factor: 9.236